Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
United Laboratories International Holdings Debt-to-Equity Related Terms
United Laboratories International Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Debt-to-Equity Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (FRA:UNJ) has a Debt-to-Equity of 0.29 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on United Laboratories International Holdings and its competitors. This is near median its historical median of 0.27. Over the past decade, United Laboratories International Holdings' Debt-to-Equity has ranged from 0.12 to 1.02. According to the industry distribution chart, United Laboratories International Holdings ranks #416 out of 813 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is United Laboratories International Holdings' Debt-to-Equity too high?
United Laboratories International Holdings' current Debt-to-Equity of 0.29 is near median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.02. The Drug Manufacturers industry median Debt-to-Equity is 0.27. United Laboratories International Holdings' value of 0.29 is 7.4% above this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #416 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Laboratories International Holdings has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #416 out of 813 companies for Debt-to-Equity. This places United Laboratories International Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.27. United Laboratories International Holdings' value of 0.29 is 7.4% above this benchmark. Historically, United Laboratories International Holdings' own Debt-to-Equity has ranged from 0.12 to 1.02 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 0.27, United Laboratories International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Debt-to-Equity of 0.29 is 7.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Debt-to-Equity is 0.29, which is near median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (FRA:UNJ) is currently considered Fairly Valued. The stock's GF Value™ is €0.94, compared to a current price of €0.92 — trading 2.7% below its estimated fair value. The current Debt-to-Equity is 0.29, which is near median its 10-year median of 0.27 and 7.4% above the Drug Manufacturers industry median of 0.27. United Laboratories International Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For United Laboratories International Holdings (FRA:UNJ), the current Debt-to-Equity is 0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (FRA:UNJ) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be undervalued.
The current stock price of €0.92 is trading 2.7% below its estimated GF Value™ of €0.94.
GuruFocus considers United Laboratories International Holdings to be Fairly Valued.
Key valuation signals for FRA:UNJ:
Debt-to-Equity: 0.29 (near median its 10-year median of 0.27)
GF Value™: €0.94 vs. price of €0.92 (2.7% below fair value)
Industry Position: 7.4% above the Drug Manufacturers median (#416 of 813)
No single metric tells the full story. See the FRA:UNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
67GF Score
Get the complete analysis for FRA:UNJ
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UNJ has been successfully added to your 
